The EIF2AK3 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the EIF2AK3 gene, which encodes the serine/threonine kinase PERK. This product comprises a heterogeneous pool of Raji B lymphoblastoid cells harboring targeted disruption of the EIF2AK3 locus, eliminating clonal selection and thereby providing a population-level knockout model. The polyclonal format captures the diversity of CRISPR/Cas9-mediated gene disruption events, offering a robust system for interrogating PERK-dependent signaling without the bias of single-cell cloning. It is ideally suited for experiments requiring bulk knockout populations where the average gene disruption across the cell pool is sufficient to reveal functional consequences.
The parental Raji cell line is an EBV-positive Burkitt lymphoma-derived B lymphoblastoid line, widely employed as a model for B-cell malignancies and immune signaling. Raji cells exhibit a mature B-cell phenotype with constitutive activation of survival pathways, making them particularly relevant for studying oncogenic mechanisms and therapeutic resistance. Their lymphoblastoid nature supports high transfection efficiency and rapid proliferation, facilitating CRISPR-based genome editing and downstream applications. This host background provides a context in which ER stress and the unfolded protein response (UPR) intersect with lymphoma biology, allowing researchers to explore how PERK influences tumor cell fitness.
EIF2AK3 (PERK) functions as a core stress sensor in the endoplasmic reticulum, where it is activated by BiP/GRP78 dissociation and subsequent dimerization/autophosphorylation upon accumulation of misfolded proteins, Ca2? depletion, or oxidative stress. Once activated, PERK directly phosphorylates the ?? subunit of eukaryotic initiation factor 2 (eIF2??) at serine 51, a pivotal event that attenuates global cap-dependent translation while selectively upregulating the transcription factor ATF4. ATF4, in turn, drives expression of CHOP/DDIT3 and GADD34/PPP1R15A, balancing adaptive and apoptotic outcomes. PERK also interacts with other UPR branches, including IRE1 and ATF6, and feeds into the integrated stress response (ISR), connecting ER stress to broader cellular fate decisions. Downstream of PERK, signaling culminates in either restoration of proteostasis or initiation of programmed cell death, primarily through CHOP-mediated transcriptional programs.
In the context of Raji B lymphoblastoid cells, PERK-mediated ER stress signaling is particularly significant for understanding B-cell lymphoma pathogenesis and therapeutic vulnerabilities. Lymphoma cells often experience heightened basal ER stress due to high secretory load and genomic instability, and PERK activation contributes to survival under these conditions. Knockout of EIF2AK3 in Raji cells disrupts this adaptive capacity, potentially sensitizing cells to ER stress-inducing agents or proteasome inhibitors. This model thus enables dissection of PERK??s role in maintaining lymphoma cell viability, modulating drug resistance, and regulating apoptosis thresholds. It also provides a platform to study how PERK intersects with oncogenic pathways specific to B-cell malignancies.
Research applications for the EIF2AK3 Knockout Raji Polyclonal Cells are extensive and include mechanistic studies of PERK-dependent signaling, UPR dynamics, and ER stress-induced apoptosis. Using this model, researchers can perform phospho-eIF2?? (Ser51) detection via Western blotting following treatment with ER stressors such as tunicamycin or thapsigargin, compare ATF4 and CHOP transcript levels by RT-qPCR, and quantify apoptosis through Annexin V/PI flow cytometry. Cell viability assays (MTT/XTT) can assess the impact of PERK loss on drug sensitivity, while co-culture and functional experiments can explore immune-related aspects of lymphoma biology. These cells are applicable across cancer research, neurodegenerative disease modeling, and diabetes investigation, where PERK plays a documented role. For additional details and ordering information, please contact Ascent Research.
